Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms
Abstract
Purpose:
Prostate circulating tumor cells escape into peripheral blood and enter bone marrow as disseminated tumor cells, representing an early step before conventionally detectable metastasis. It is unclear how frequently this occurs in localized disease and existing detection methods rely on epithelial markers with low specificity and sensitivity. We used multiple methodologies of disseminated tumor cell detection in bone marrow harvested at radical prostatectomy.
Materials and Methods:
Bone marrow was harvested from 208 clinically localized cases, 16 controls and 5 metastatic cases with peripheral blood obtained from 37 metastatic cases. Samples were evaluated at 4 centers with 4 distinct platforms using antibody enrichment with the AdnaTest (Qiagen®) or VERSA (versatile exclusion based rare sample analysis), or whole sample interrogation with the RareCyte platform (Seattle, Washington) or HD-SCA (high definition single cell assay) using traditional epithelial markers and prostate specific markers. We investigated the sensitivity and specificity of these markers by evaluating expression levels in control and metastatic cases.
Results:
EpCAM, NKX3.1 and AR were nonspecifically expressed in controls and in most samples using AdnaTest with no relation to perioperative variables. Only 1 patient with localized disease showed positive results for the prostate specific marker PSA. With the VERSA platform no localized case demonstrated disseminated tumor cells. With the RareCyte and HD-SCA platforms only a single patient had 1 disseminated tumor cell.
Conclusions:
Evaluation across multiple platforms revealed that epithelial markers are nonspecific in bone marrow and, thus, not suitable for disseminated tumor cell detection. Using prostate specific markers disseminated tumor cells were typically not detected in patients with localized prostate cancer.
References
- 1 : Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res2008; 14: 5013. Google Scholar
- 2 : High-resolution genomic profiling of disseminated tumor cells in prostate cancer. J Mol Diagn2016; 18: 131. Google Scholar
- 3 : Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res2009; 15: 677. Google Scholar
- 4 : Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget2014; 5: 9939. Google Scholar
- 5 : Combined genome and transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients reveals unexpected transcriptomes. Cancer Res2014; 74: 7383. Google Scholar
- 6 : Single cell transcriptomic analysis of prostate cancer cells. BMC Mol Biol2013; 14: 6. Google Scholar
- 7 : mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. PLoS One2012; 7: e49144. Google Scholar
- 8 : Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. BJU Int2017; 120: E30. Google Scholar
- 9 : Monoclonal antibody 9C4 recognizes epithelial cellular adhesion molecule, a cell surface antigen expressed in early steps of erythropoiesis. Exp Hematol2002; 30: 537. Google Scholar
- 10 : Spectrum of cytokeratin-positive cells in the bone marrows of colorectal carcinoma patients. Anticancer Res2004; 24: 2375. Google Scholar
- 11 : Identification of TROP2 (TACSTD2), an EpCAM-like molecule, as a specific marker for TGF-β1-dependent human epidermal Langerhans cells. J Invest Dermatol2011; 131: 2049. Google Scholar
- 12 : Localization of androgen receptor expression in human bone marrow. J Pathol2001; 193: 361. Google Scholar
- 13 : Tissue-based map of the human proteome. Science2015; 347: 1260419. Google Scholar
- 14 : Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA2005; 294: 433. Google Scholar
- 15 : Integrative clinical genomics of advanced prostate cancer. Cell2015; 161: 1215. Google Scholar
- 16 : Can we stop prostate specific antigen testing 10 years after radical prostatectomy?. J Urol2011; 186: 500. Link, Google Scholar
- 17 : Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol2000; 164: 101. Link, Google Scholar
- 18 : Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol2008; 26: 4928. Google Scholar
- 19 : Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res2008; 14: 6302. Google Scholar
- 20 : Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol2008; 26: 3213. Google Scholar
- 21 : Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res2006; 12: 4218. Google Scholar
- 22 : A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells. Small2014; 10: 4895. Google Scholar
